BTIG Starts Ironwood Pharmaceuticals (IRWD) at Buy
Get Alerts IRWD Hot Sheet
Rating Summary:
14 Buy, 11 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
BTIG initiated coverage on Ironwood Pharmaceuticals (NASDAQ: IRWD) with a Buy rating and a price target of $15. Analyst Timothy Chiang noted that Linzess was steadily ramping and Viberzi was launching.
Chiang said, "We believe IRWD shares are attractive based on improving visibility with its GI-focused pipeline ... With 2015-18 revenues forecasted at $140 million, $225 million, $303 million, and $385 million, respectively, we estimate IRWD to reach profitability in 2017, with forecasted EPS of $1.06 in 2019.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $11.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Grindr (GRND) at Buy
- LTIMindtree Ltd (LTIM:IN) PT Lowered to INR4,800 at Morgan Stanley
- CLSA Downgrades SF Holding Co Ltd (002352:CH) to Outperform (2)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!